Mount Sinai scientists recognized with Global AI Prize for novel Alzheimer’s disease research platform
Grant and Award Announcement
Updates every hour. Last Updated: 27-May-2026 00:16 ET (27-May-2026 04:16 GMT/UTC)
A team led by Dr. Kuan-lin Huang, PhD, has been named a winner of the $1 million Alzheimer’s Insights AI Prize, the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced on March 20. Dr. Huang is an Associate Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. The award honors the development of Biomni-AD, an advanced AI-powered “co-scientist” designed to dramatically reduce the time required to generate scientific insights from complex biomedical data. The Mount Sinai team collaborated with partners at Stanford University on the winning project. Originally conceived as a single $1 million award, the competition expanded to recognize two winning teams, doubling the total prize amount to $2 million—reflecting both the exceptional quality of submissions and the urgency of advancing new approaches to Alzheimer’s disease and related dementias.
Living pharmacies use engineered cells to produce medicines inside the body. System integrates the cells with oxygen-producing bioelectronics in one wireless, fully implantable device. In animal studies, the device stably produced three different biologic drugs with three different half lives.
St. Jude Children’s Research Hospital scientists studied how prompting styles influence artificial intelligence’s ability to analyze interviews and identify childhood cancer survivors needing extra support.
Scientists at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine developed BiliSeq, a molecular test that detected bile duct cancer with twice the sensitivity of the standard test, giving physicians a more accurate picture of the patient’s diagnosis.